54gene
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
54gene developed a genetic-testing platform for healthcare applications.
02 / 54gene FAILURE REASONS
Failure reasons
54gene failed from a combination of reckless spending, capital intensity, and leadership chaos. After its 2021 diagnostics venture (Seven River Labs) generated over $20 million from COVID-19 testing, the company spent lavishly without regard for the economics of the diagnostics space, while its core genomics research demanded heavy capital it could not raise. By mid-2022 it had run out of money, cutting salaries and laying off staff. Founder Abasi Ene-Obong stepped down in October 2022, triggering three CEO transitions in under a year, governance disputes, and allegations of questionable executive spending. A failed fundraising slashed the valuation from about $170 million to about $50 million.
03 / EVENT HISTORY
Events in the structured record
- Product or service closed
Then-CEO Ron Chiarello told TechCabal the company could not continue to operate financially and began winding down in July 2023; by September the website was gone. This is a company-level operational shutdown, not a product-only sunset. Later 2025 court coverage of asset-sale disputes is subsequent, not the 2023 ending event.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
54gene began its shutdown process in July 2023; by September its website was inaccessible and its long-standing PR agency confirmed it had severed ties.
- 02
The company ceased operations amid unpaid creditors and internal disputes; former interim CEO Teresia Bost sued, alleging the company was near insolvency and citing questionable executive spending.
- 03
In 2025, a Nigerian court blocked the sale of company assets - including a biobank of genomic data from 100,000 Nigerians valued at $3 million - amid a legal clash between founder Abasi Ene-Obong and investors Cathay AfricInvest Innovation Fund and Adjuvant Capital.